lncRNA ST3GAL6‑AS1 promotes invasion by inhibiting hnRNPA2B1‑mediated ST3GAL6 expression in multiple myeloma.

Publisher: D.A. Spandidos Country of Publication: Greece NLM ID: 9306042 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1791-2423 (Electronic) Linking ISSN: 10196439 NLM ISO Abbreviation: Int J Oncol Subsets: MEDLINE

Publication: <2003->: Athens, Greece : D.A. Spandidos
Original Publication: Athens, Greece : Lychnia,

Gene Expression Regulation, Neoplastic*; Heterogeneous-Nuclear Ribonucleoprotein Group A-B/*metabolism ; Multiple Myeloma/*pathology ; RNA, Long Noncoding/*genetics ; Sialyltransferases/*metabolism; Adult ; Aged ; Cell Line, Tumor ; Cell Movement ; Cell Proliferation ; Female ; Humans ; Male ; Middle Aged ; Multiple Myeloma/genetics ; Multiple Myeloma/metabolism ; Neoplasm Invasiveness ; beta-Galactoside alpha-2,3-Sialyltransferase

Multiple myeloma (MM) is an incurable disease caused by the infiltration of malignant plasma B cells into bone marrow, whose pathogenesis remains largely unknown. Long non‑coding RNAs (lncRNAs) have emerged as important factors in pathogenesis. Our previous study validated that lncRNA ST3 β‑galactoside α‑2,3‑sialyltransferase 6 antisense RNA 1 (ST3GAL6‑AS1) was upregulated markedly in MM. Therefore, the aim of the study was to investigate the molecular mechanisms of ST3GAL6‑AS1 in MM cells. ST3GAL6‑AS1 expression levels in MM cells was detected using reverse transcription‑quantitative PCR. ST3GAL6‑AS1 antisense oligonucleotides and small interfering RNAs were transfected into MM cells to downregulate expression. In vitro assays were performed to investigate the functional role of ST3GAL6‑AS1 in MM cells. RNA pull‑down, RNA immunoprecipitation and comprehensive identification of RNA‑binding proteins using mass spectrometry assays were used to determine the mechanism of ST3GAL6‑AS1‑mediated regulation of underlying targets. It was reported that knockdown of ST3GAL6‑AS1 suppressed the adhesion, migration and invasion ability of MM cells in vitro . Expression of ST3GAL6 was significantly reduced when ST3GAL6‑AS1 was knock downed in MM cells. Moreover, mechanistic investigation showed that ST3GAL6‑AS1 could suppress ST3GAL6 mRNA degradation via interacting with heterogeneous nuclear ribonucleoprotein A2B1 (hnRNPA2B1). The present results suggested that upregulated lncRNA ST3GAL6‑AS1 promotes adhesion and invasion of MM cells by binding with hnRNPA2B1 to regulate ST3GAL6 expression.

J Exp Clin Cancer Res. 2015 Sep 11;34:102. (PMID: 26362431)
Yi Chuan. 2017 Mar 20;39(3):189-199. (PMID: 28420615)
Hum Genet. 2016 Aug;135(8):851-67. (PMID: 27215579)
Oncogene. 2007 Jul 19;26(33):4877-81. (PMID: 17297456)
Lancet Oncol. 2014 Nov;15(12):e538-48. (PMID: 25439696)
Int J Mol Sci. 2016 Aug 09;17(8):. (PMID: 27517905)
Cancer Lett. 2013 Jun 10;333(2):213-21. (PMID: 23354591)
BMC Cancer. 2014 Nov 04;14:809. (PMID: 25369863)
Eur J Haematol. 2017 Sep;99(3):223-233. (PMID: 28543758)
Am J Hematol. 2020 May;95(5):548-567. (PMID: 32212178)
Lancet Oncol. 2016 Aug;17(8):e328-e346. (PMID: 27511158)
Leukemia. 2018 Oct;32(10):2250-2262. (PMID: 29632340)
Trends Genet. 2017 Oct;33(10):665-676. (PMID: 28870653)
Int J Mol Sci. 2019 Feb 10;20(3):. (PMID: 30744200)
Cell Mol Life Sci. 2016 Jul;73(13):2491-509. (PMID: 27007508)
J Biol Chem. 2014 Oct 17;289(42):29365-75. (PMID: 25187517)
Cell Rep. 2016 May 3;15(5):926-934. (PMID: 27117401)
Mayo Clin Proc. 2013 Apr;88(4):360-76. (PMID: 23541011)
Cancer Treat Rev. 2018 Nov;70:199-208. (PMID: 30245231)
Clin Exp Pharmacol Physiol. 2017 Oct;44(10):1032-1041. (PMID: 28664617)
Hepatology. 2020 Jan;71(1):112-129. (PMID: 31148184)
Int J Oncol. 2019 Jun;54(6):2157-2168. (PMID: 31081061)
Life Sci. 2020 May 15;249:117503. (PMID: 32142767)
Nat Rev Dis Primers. 2017 Jul 20;3:17046. (PMID: 28726797)
Oncogene. 2002 Jan 21;21(4):580-3. (PMID: 11850782)
Science. 2019 Aug 16;365(6454):. (PMID: 31320558)
Oncol Lett. 2017 Aug;14(2):2446-2452. (PMID: 28781681)
Cells. 2020 Mar 03;9(3):. (PMID: 32138182)
Int J Cancer. 2019 Jul 15;145(2):450-460. (PMID: 30613961)
J Biochem Mol Toxicol. 2018 Jan;32(1):. (PMID: 29205703)
JAMA Oncol. 2019 Dec 1;5(12):1749-1768. (PMID: 31560378)
Hepatology. 2016 Jul;64(1):58-72. (PMID: 26663205)
Leukemia. 2018 Feb;32(2):252-262. (PMID: 29257139)
Cell Mol Life Sci. 2009 Apr;66(7):1239-56. (PMID: 19099192)
Br J Haematol. 2017 Nov;179(3):449-460. (PMID: 28770558)
Biochem Biophys Res Commun. 2018 Jul 12;502(2):194-201. (PMID: 29800569)
Blood. 2014 Sep 11;124(11):1765-76. (PMID: 25061176)
Methods. 2001 Dec;25(4):402-8. (PMID: 11846609)
Cell. 2018 Jan 25;172(3):393-407. (PMID: 29373828)
FEBS J. 2014 Aug;281(16):3766-75. (PMID: 24988946)
Blood Cancer J. 2018 Jan 12;8(1):7. (PMID: 29330358)
J Clin Invest. 2020 Jan 2;130(1):404-421. (PMID: 31593555)
Life Sci. 2018 Mar 1;196:133-142. (PMID: 29459023)
Cancer Sci. 2017 Feb;108(2):267-276. (PMID: 27906498)
Leukemia. 2018 Sep;32(9):1948-1957. (PMID: 29487387)
Blood. 2017 Nov 2;130(18):1965-1975. (PMID: 28928124)
Genes (Basel). 2018 Feb 01;9(2):. (PMID: 29389884)

Keywords: multiple myeloma; ST3GAL1-AS1; adhesion; invasion; heterogeneous nuclear ribonucleoprotein A2B1; ST3GAL6

0 (Heterogeneous-Nuclear Ribonucleoprotein Group A-B)
0 (RNA, Long Noncoding)
EC 2.4.99.- (Sialyltransferases)
EC 2.4.99.4 (beta-Galactoside alpha-2,3-Sialyltransferase)
EC 2.4.99.4 (ST3GAL1 protein, human)

Date Created: 20210302 Date Completed: 20211103 Latest Revision: 20221207

20221213

PMC7895539

10.3892/ijo.2021.5185

33649796